TABLE 8.

Outcomes of published studies using integrin inhibitors for the treatment of recurrent glioblastoma

Authors & Year	Study Type & Trial Phase	No. of Patients	Prior Treatment	Current Intervention & Regimen	Radiographic Response	PFS	OS
cilengitide	BBB permeability: adequate
Reardon et al., 2008	Phase II clinical trial,  randomized,  parallel arm	81: cilengitide high dose  (n = 40); cilengitide  low dose (n = 41)	surgery, radiotherapy,  no more than 1  chemotherapy	cilengitide high dose  or cilengitide low  dose	cilengitide high dose:  CR (0%), PR (13%);  cilengitide low dose:  CR (0%), PR (5%)	cilengitide high dose: 15% at  6 mos, median 2.0 mos;  cilengitide low dose: 10%  at 6 mos, median 2.0 mos	cilengitide high  dose: 9.9 mos;  cilengitide low  dose: 6.5 mos
Gilbert et al., 2012	Phase II clinical trial,  single arm	30	did not specify	cilengitide + surgery	NA	12% at 6 mos, median 2 mos	NA